EMA (EU)
GUIDANCE FINAL
Concept paper on the revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 15 - Qualification and validation - Corrigendum
Published: 7/15/2026Detected: 7/15/2026
Summary preview
Extends and strengthens EMA Annex 15 Qualification and Validation expectations from an optional supplementary guide toward mandatory-aligned implementation for active substance (chemical and biological) manufacturers…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026